Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 1, 2011, Pages 50-58

  Ning, Yun ^a   Zhen, Wei ^b   Fu, Zhuo ^b   Jiang, Jenny ^a   Liu, Dongmin ^b   Belardinelli, Luiz ^a   Dhalla, Arvinder K ^a  

^a Gilead Sciences ^*  (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; GLUCOSE; HEMATOXYLIN; HEMOGLOBIN A1C; INSULIN; RANOLAZINE; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL SURVIVAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN TOLERANCE TEST; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; WEIGHT REDUCTION;

ACETANILIDES; ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BLOOD GLUCOSE; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; PIPERAZINES; RATS;

EID: 79953014923     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.176396     Document Type: Article

References (39)

1. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ, and INVEST Investigators (2004) Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension 44:637-642. (Pubitemid 39435232)
2. Bratanova-Tochkova TK, Cheng H, Daniel S, Gunawardana S, Liu YJ, Mulvaney-Musa J, Schermerhorn T, Straub SG, Yajima H, and Sharp GW (2002) Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 51 (Suppl 1):S83-S90. (Pubitemid 34761499)
3. Cannon CP (2008) Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol 102:5L-9L.
4. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, et al. (2004) Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43:1375-1382. (Pubitemid 38496341)
5. Chisholm JW, Goldfine AB, Dhalla AK, Braunwald E, Morrow DA, Karwatowska-Prokopczuk E, and Belardinelli L (2010) Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 33:1163-1168.
6. Corbett JA, Wang JL, Hughes JH, Wolf BA, Sweetland MA, Lancaster JR, Jr, and McDaniel ML (1992a) Nitric oxide and cyclic GMP formation induced by interleukin 1 beta in islets of Langerhans. Evidence for an effector role of nitric oxide in islet dysfunction. Biochem J 287:229-235.
7. Corbett JA, Wang JL, Sweetland MA, Lancaster JR Jr, and McDaniel ML (1992b) Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J Clin Invest 90:2384-2391. (Pubitemid 23010057)
8. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:895-906. (Pubitemid 41265663)
9. Derr R, Garrett E, Stacy GA, and Saudek CD (2003) Is HbA(1c) affected by glycemic instability? Diabetes Care 26:2728-2733.
10. Dhalla AK, Liu D, Santikul M, and Belardinelli L (2008) Ranolazine increases glucose-stimulated insulin secretion in-vitro and in-vivo (abstract). J Am Coll Cardiol 51 (Suppl):A321.
11. Ding WG and Kitasato H (1997) Suppressing Na+ influx induces an increase in intracellular ATP concentration in mouse pancreatic beta-cells. Jpn J Physiol 47:299-306.
12. 2+-dependent insulin exocytosis. J Cell Sci 117:3119-3127.
13. Kang JH, Chang SY, Jang HJ, Kim DB, Ryu GR, Ko SH, Jeong IK, Jo YH, and Kim MJ (2009) Exendin-4 inhibits interleukin-1beta-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F beta-cells. J Endocrinol 202:65-75.
14. Kwon NS, Lee SH, Choi CS, Kho T, and Lee HS (1994) Nitric oxide generation from streptozotocin. FASEB J 8:529-533. (Pubitemid 24161126)
15. LeDoux SP, Woodley SE, Patton NJ, and Wilson GL (1986) Mechanisms of nitrosourea-induced beta-cell damage. Alterations in DNA. Diabetes 35:866-872. (Pubitemid 16014437)
16. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, and Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478. (Pubitemid 36043598)
17. Liu D, Zhen W, Yang Z, Carter JD, Si H, and Reynolds KA (2006) Genistein acutely stimulates insulin secretion in pancreatic beta-cells through a cAMP-dependent protein kinase pathway. Diabetes 55:1043-1050. (Pubitemid 44100180)
18. Liu GY and An ZM (2009) [Protective effect of rosiglitazone sodium on islet beta-cell of STZ induced diabetic rats through JNK pathway]. Sichuan Da Xue Xue Bao Yi Xue Ban 40:430-434.
19. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, et al. (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704. (Pubitemid 44324122)
20. Newsholme P, Brennan L, Rubi B, and Maechler P (2005) New insights into amino acid metabolism, beta-cell function and diabetes. Clin Sci (Lond) 108:185-194. (Pubitemid 40343565)
21. Papaccio G, Frascatore S, Esposito V, and Pisanti FA (1991) Early macrophage infiltration in mice treated with low-dose streptozocin decreases islet superoxide dismutase levels: prevention by silica pretreatment. Acta Anat (Basel) 142:141-146.
22. Papaccio G, Linn T, and Chieffi Baccari G (1993) Morphological observations on pancreatic islet blood vessels in low-dose streptozocin-treated mice. J Anat 182:45-53. (Pubitemid 23124876)
23. Papaccio G, Pisanti FA, Latronico MV, Ammendola E, and Galdieri M (2000) Multiple low-dose and single high-dose treatments with streptozotocin do not generate nitric oxide. J Cell Biochem 77:82-91. (Pubitemid 30126897)
24. Pepine CJ and Cooper-Dehoff RM (2004) Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol 44:509-512. (Pubitemid 39078171)
25. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, et al. (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290:2805-2816. (Pubitemid 37509488)
26. Portha B, Blondel O, Serradas P, McEvoy R, Giroix MH, Kergoat M, and Bailbe D (1989) The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabete Metab 15:61-75. (Pubitemid 19140020)
27. Rosati B, Marchetti P, Crociani O, Lecchi M, Lupi R, Arcangeli A, Olivotto M, and Wanke E (2000) Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: the role of HERG K(+) channels in firing and release. Faseb J 14:2601-2610.
28. Rutter GA (2001) Nutrient-secretion coupling in the pancreatic islet beta-cell: recent advances. Mol Aspects Med 22:247-284.
29. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, et al. (2007) Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116:1647-1652. (Pubitemid 47537839)
30. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, and ERICA Investigators (2006) Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 48:566-575. (Pubitemid 44093970)
31. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, and Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412. (Pubitemid 30609442)
32. Sun N, Yang G, Zhao H, Savelkoul HF, and An L (2005) Multidose streptozotocin induction of diabetes in BALB/c mice induces a dominant oxidative macrophage and a conversion of TH1 to TH2 phenotypes during disease progression. Mediators Inflamm 2005:202-209.
33. Takamura T, Ando H, Nagai Y, Yamashita H, Nohara E, and Kobayashi K (1999) Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res Clin Pract 44:107-114. (Pubitemid 29447676)
34. Timmis AD, Chaitman BR, and Crager M (2006) Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 27:42-48. (Pubitemid 41785931)
35. UK Prospective Diabetes Study (UKPDS) Group (1998a) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865.
36. UK Prospective Diabetes Study (UKPDS) Group. (1998b) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853.
37. Wajchenberg BL (2007) beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28:187-218.
38. Wofford MR and King DS (2004) Relationship between antihypertensive drugs and metabolic syndrome. Metab Syndr Relat Disord 2:308-314. (Pubitemid 40846903)
39. Yang Z, Chen M, Ellett JD, Fialkow LB, Carter JD, and Nadler JL (2004) The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. Transplantation 77:55-60. (Pubitemid 38116872)